AZ launches Zomig nasal spray

pharmafile | October 21, 2003 | News story | |   

AstraZeneca has launched a new fast acting nasal spray version of its migraine treatment Zomig.

The product is intended to bypass many of the problems associated with conventional tablets and subcutaneous injections and bring relief of symptoms within 15 minutes.

Nausea and vomiting during attacks mean some migraine patients find tablets difficult to take, and also slow to take effect, whereas a dislike of needles dissuades many from using injectable formulations.

Advertisement

Dr Andrew Dowson, Director of King Headache Services, King's College Hospital, London, UK says: "The symptoms of migraine vary enormously and sufferers need a choice of treatment. Doctors need to take a patient need and preferences into account when treating migraine and a range of formulations is required to ensure that patients get optimal therapy every time".

GlaxoSmithKline's Imigran (like Zomig, a member of the triptan drug class) is the most prescribed product in the UK migraine market, with 645,000 prescriptions written in England last year. Imigran is also available in a nasal spray formulation.

Sales of Zomig outside the US increased by 18% in the first nine months of 2002, with a 35% growth in France.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content